StockData

HUTCHMED (China) vs Nuvation Bio

HCM and NUVB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HCM and NUVB compare

Nuvation Bio grew revenue faster over the last twelve months (1084% versus −13.0% for HUTCHMED (China)).

HUTCHMED (China) keeps more of each dollar of sales as profit, with a net margin of 83.3% compared with −88.2% at Nuvation Bio.

HUTCHMED (China) scores higher on the StockData Score (5 against 4 for Nuvation Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHCMNUVB
Size and price
Market cap–$1.4B
Share price$14.40$3.90
Change, 1 year−4.5%−19.8%
Change, 5 years−59.1%−52.3%
Beta (5Y)0.751.77
Employees109298
StockData Score
Total score5 (better)4
Valuation score00
Growth score01 (better)
Performance score3 (better)1
Health score22
Dividend score00
Valuation
P/S–8.1×
P/B–5.4×
Fair value–$1.89
Margin of safety–−107%
Growth
Revenue growth (TTM)−13.0%1084% (better)
Revenue growth, 5Y average19.2%–
Net income growth (TTM)1111%–
EPS growth (TTM)1200%–
Profitability
Gross margin38.7%–
Operating margin−7.1% (better)−81.0%
Net margin83.3% (better)−88.2%
FCF margin−14.4%–
Return on equity36.7% (better)−47.8%
Financial health
Debt / equity0.090.02 (better)
Interest coverage−13.7×−5.4× (better)
Current ratio5.648.37 (better)
Altman Z-score–0.12
Piotroski F-score44
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.51%66.5%
Held by insiders0.44%24.6%
Insider net buying, 12 months–−$4.5M
Superinvestors holding–2
Short interest, % of float–23.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.